Ribosome Profiling for Novel Antigen Discovery.

Area of Science:

• Oncology
• Immunology
• Proteomics

Background:

• Traditional cancer antigen discovery methods miss novel targets like splice isoforms, gene fusions, and novel or unannotated open reading frames (nuORFs).
• These novel antigens present promising opportunities for cancer immunotherapy due to their potential abundance and immunogenicity.

Purpose of the Study:

• To explore the use of ribosome profiling (Ribo-seq) and mass spectrometry (MS)-based proteomics for novel cancer antigen discovery.
• To highlight the potential of combining Ribo-seq with proteogenomic approaches for identifying new immunotherapeutic targets.

Main Methods:

• Ribosome profiling (Ribo-seq) to assess and verify the translation of novel or unannotated open reading frames (nuORFs).
• Mass spectrometry (MS)-based proteomics to validate protein and peptide expression identified by Ribo-seq.
• Proteogenomic approaches integrating Ribo-seq and MS data for comprehensive antigen discovery.

Main Results:

• Ribo-seq effectively identifies translated nuORFs, offering a rich source of potential cancer antigens.
• MS-based proteomics validates the expression of these novel translated products, confirming their presence as antigens.
• The combined proteogenomic strategy enhances the discovery of novel cancer antigens missed by conventional methods.

Conclusions:

• Combining Ribo-seq with MS-based proteomics is a powerful strategy for discovering novel cancer antigens.
• This approach significantly expands the repertoire of potential targets for developing more effective cancer immunotherapies.
• Further research into these novel antigens could lead to breakthroughs in personalized cancer treatment.